-
Affimed Therapeutics (AFMD) PT Raised to $6 at BMO Capital
-
Affimed Therapeutics (AFMD) PT Raised to $5 at BMO Capital
-
Affimed Therapeutics (AFMD) PT Lowered to $4 at BMO Capital
-
Affimed Announces Closing of Public Offering of Common Stock
-
Affimed (AFMD) Prices 10M Share Offering at $1.80
-
Affimed Announces Pricing of Public Offering of Common Stock
-
Affimed Announces Proposed Public Offering of Common Stock
-
Affimed (AFMD) to Offer Common Shares
-
Affimed Announces Proposed Public Offering of Common Stock
-
BMO Capital Starts Affimed Therapeutics (AFMD) at Outperform
-
Affimed N.V. Announces Closing of Public Offering of Common Stock and Exercise of Underwriters' Option to Purchase Additional Shares
-
Affimed N.V. Announces Pricing of Public Offering of Common Stock
-
Affimed N.V. Announces Proposed Public Offering of Common Stock
-
Affimed (AFMD) Files to Offer $35M in Common Stock
-
Affimed N.V. Announces Proposed Public Offering of Common Stock
-
BMO Capital Sees Potential Best-In-Class EGFRv111 Antibody from Affimed Therapeutics (AFMD)
-
BMO Capital Starts Affimed Therapeutics (AFMD) at Outperform
-
Affimed Therapeutics (AFMD) IPO Opens Lower
-
Affimed Therapeutics (AFMD) Prices 8M Common IPO at $7/Share

